Jurkat-Human TIGIT (Luc)-Reporter Cell
| Catalog Number | CBCL-0598 |
| Price | Online Inquiry |
| Unit Quantity | 5 x 10^6 cells / 1.0 ml |
Introduction
The Jurkat-Human TIGIT (Luc)-Reporter Cell is engineered to express the NFAT response element driving luciferase expression systems and the receptor full-length human TIGIT (Gene ID: 201633), which can be used to evaluate the potency of TIGIT blockade. When co-cultured with target cells expressing human CD155, the TIGIT/CD155 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the TIGIT/CD155 interaction by either anti-TIGIT or anti-CD155 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.
Application
Screen for anti-human TIGIT or anti-human CD155 antibody.
Background
TIGIT (T Cell Immunoreceptor with Ig and ITIM Domains) is an inhibitory receptor expressed on T cells and NK cells. It binds to CD155 (PVR) and CD112 (Nectin-2) on tumor cells and APCs, delivering inhibitory signals that suppress cytotoxicity and cytokine production. TIGIT synergizes with PD-1 to promote immune evasion in cancer.
Product Information
| Category | Immune Checkpoint Cell Lines |
| Cell Line Name | Jurkat-Human TIGIT (Luc)-Reporter Cell |
| Protein Family | T cell immunoreceptor with Ig and ITIM domains family |
| Gene | TIGIT |
| Species | Human |
| Host Cell Line | Jurkat |
| Cell Type | Human T-cell leukemia |
| Morphology | Lymphoblastoid |
| Growth Properties | Suspension |
| Storage Method | Frozen in liquid nitrogen. |
| Stability | Validated for at least 10 passages |
| Mycoplasma | Negative |
| Sterility Testing | Negative |
| Shipping | Shipping in dry ice |
| Caution | For Research Use Only |